AbCellera Biologics Inc (OQ:ABCL)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2215 Yukon Street
VANCOUVER BC V5Y 0A1
Tel: N/A
Website: https://www.abcellera.com
IR: See website
<
Key People
Carl L.G. Hansen
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Veronique Lecault
Co-Founder, Chief Operating Officer, Director
Andrew Booth
Chief Financial Officer
Tryn T. Stimart
Chief Compliance Officer, Corporate Secretary, Chief Legal Officer
Neil Aubuchon
Chief Commercial Officer
 
Business Overview
AbCellera Biologics Inc. (AbCellera) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
Financial Overview
For the six months ended 30 June 2022, AbCellera Biologics Inc revenues increased 57% to $362.5M. Net income increased 41% to $161.8M. Revenues reflect Royalty revenue increase of 77% to $340.2M, Research fees increase from $9.2M to $21.9M. Net income was partially offset by Royalty fees increase from $23.6M to $49.8M (expense), Research and development - Balancing val increase of 99% to $40.9M (expense).
Employees: 386 as of Dec 31, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $3,110M as of Jun 30, 2022
Annual revenue (TTM): $507.34M as of Jun 30, 2022
EBITDA (TTM): $286.60M as of Jun 30, 2022
Net annual income (TTM): $200.36M as of Jun 30, 2022
Free cash flow (TTM): $286.77M as of Jun 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 285,138,643 as of Aug 4, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.